Posted inNews and Updates
FDA Advisory Committee Backs Compounded Peptides
FDA advisors recently signaled support for compounded peptides. Learn how this regulatory shift impacts clinical access and pharmacy standards.
Posted inNews and Updates
New EU Regulations to Boost Clinical Trial Transparency
European regulators are mandating stricter clinical trial transparency to reduce bias and improve patient safety in global medical research. Read more.
Posted inNews and Updates
New Breast Cancer Trial Shows Promise in HER2+ Patients
A groundbreaking breast cancer trial at UAB shows promising results for a HER2+ patient, offering a potential new path for aggressive cancer treatment.
Posted inNews and Updates
Johnson & Johnson Secures FDA Approval for OTTAVA System
Johnson & Johnson receives FDA clearance for the OTTAVA surgical system. Discover how this innovative, space-saving robotic platform will transform surgery.
Posted inNews and Updates
AI Breakthrough Identifies New Drug Targets for Psoriasis
Researchers use AI to discover new drug targets for psoriasis, offering hope for more effective treatments for patients with treatment-resistant skin disease.
Posted inNews and Updates
Dexcom Joins FDA-CMS Pilot to Streamline Health Tech Access
Dexcom joins a new FDA-CMS pilot program aimed at streamlining the path for medical devices, potentially accelerating patient access to critical technology.
Posted inNews and Updates
Armored CAR-T Therapy Shows Promise in Advanced Liver Cancer
New research in Nature highlights a breakthrough armored GPC3 CAR-T therapy, showing potential to treat advanced liver cancer by overcoming tumor defenses.
Posted inNews and Updates
New Clinical Trial Legislation: A Guide for Researchers
Stay updated on the latest clinical trial legislation changes. Learn how new regulatory shifts affect research efficiency, data transparency, and compliance.
Posted inNews and Updates
Retatrutide Success: Lilly’s Triple Agonist Hits Weight Goals
Lilly's retatrutide achieves major success in Phase 3 trials, showing significant weight loss and improved A1C levels via a novel triple-agonist approach.
Posted inNews and Updates
Vortosiran Shows Promise in Phase IIa Coronary Disease Trial
Ribo’s Phase IIa trial for vortosiran shows positive safety and biomarker results in treating coronary artery disease. Learn about this new approach.